ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $615,500.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of the company’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.31, for a total transaction of $615,500.00. Following the completion of the sale, the director now directly owns 210,346 shares in the company, valued at approximately $2,589,359.26. The trade was a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Laura Shawver also recently made the following trade(s):

• On Monday, January 6th, Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00.
• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total value of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The shares were sold at an average price of $13.75, for a total value of $203,115.00.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock opened at $12.80 on Friday. ARS Pharmaceuticals, Inc. has a 1-year low of $6.29 and a 1-year high of $18.51. The stock’s 50 day moving average price is $12.37 and its 200 day moving average price is $13.13. The company has a market cap of $1.24 billion, a PE ratio of -25.10 and a beta of 0.99.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on SPRY. Raymond James raised their price objective on shares of ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partners lifted their target price on ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Four equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $26.00.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. nVerses Capital LLC acquired a new position in shares of ARS Pharmaceuticals in the third quarter worth $30,000. Compass Capital Corp MA ADV purchased a new stake in ARS Pharmaceuticals during the 4th quarter worth about $106,000. Quarry LP acquired a new position in ARS Pharmaceuticals in the 3rd quarter valued at about $174,000. TFG Advisers LLC purchased a new stake in shares of ARS Pharmaceuticals during the third quarter worth about $180,000. Finally, Stifel Financial Corp acquired a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $199,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.